PORTFOLIO NEWS Constellation Pharmaceuticals to be Acquired by MorphoSys June 2, 2021 Read More » Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease June 2, 2021 Read More » Kallyope Inc. Appoints Patrick Flanigan as Chief Financial Officer June 1, 2021 Read More » eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies May 27, 2021 Read More » Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference May 24, 2021 Read More » NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH May 24, 2021 Read More » Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy May 20, 2021 Read More » Escient Pharmaceuticals Appoints Christian Weyer, M.D., M.A.S., As President And Chief Medical Officer May 17, 2021 Read More » RAPT Therapeutics Reports First Quarter 2021 Financial Results May 11, 2021 Read More » Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress May 10, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease June 2, 2021 Read More »
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies May 27, 2021 Read More »
Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference May 24, 2021 Read More »
NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH May 24, 2021 Read More »
Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy May 20, 2021 Read More »
Escient Pharmaceuticals Appoints Christian Weyer, M.D., M.A.S., As President And Chief Medical Officer May 17, 2021 Read More »
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress May 10, 2021 Read More »
